- Home
- PBYI
as of 03-18-2026 3:58pm EST
$6.00
$0.14
-2.28%
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | LOS ANGELES |
| Market Cap: | 263.4M | IPO Year: | 2011 |
| Target Price: | N/A | AVG Volume (30 days): | 439.4K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.61 | EPS Growth: | -1.61 |
| 52 Week Low/High: | $2.58 - $7.68 | Next Earning Date: | 05-29-2026 |
| Revenue: | $27,685,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | -2.63% | Revenue Growth (next year): | N/A |
| P/E Ratio: | 10.03 | Index: | N/A |
| Free Cash Flow: | 41.7M | FCF Growth: | +7.38% |
AI-Powered PBYI Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 73.33%
73.33%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Puma Biotechnology Inc (PBYI)
NOUGUES MAXIMO F
Sell
Chief Financial Officer
PBYI Jan 7, 2026
Avg Cost/Share
$5.88
Shares
6,405
Total Value
$37,654.99
Owned After
193,284
SEC Form 4
HUNT DOUGLAS M
Sell
See Remarks
PBYI Jan 7, 2026
Avg Cost/Share
$5.88
Shares
5,014
Total Value
$29,477.31
Owned After
155,907
SEC Form 4
AUERBACH ALAN H
Sell
President and CEO
PBYI Jan 7, 2026
Avg Cost/Share
$5.88
Shares
18,012
Total Value
$105,892.55
Owned After
7,145,951
SEC Form 4
NOUGUES MAXIMO F
Sell
Chief Financial Officer
PBYI Jan 6, 2026
Avg Cost/Share
$5.84
Shares
4,540
Total Value
$26,531.76
Owned After
193,284
SEC Form 4
HUNT DOUGLAS M
Sell
See Remarks
PBYI Jan 6, 2026
Avg Cost/Share
$5.84
Shares
3,973
Total Value
$23,218.21
Owned After
155,907
SEC Form 4
AUERBACH ALAN H
Sell
President and CEO
PBYI Jan 6, 2026
Avg Cost/Share
$5.84
Shares
16,938
Total Value
$98,985.67
Owned After
7,145,951
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| NOUGUES MAXIMO F | PBYI | Chief Financial Officer | Jan 7, 2026 | Sell | $5.88 | 6,405 | $37,654.99 | 193,284 | |
| HUNT DOUGLAS M | PBYI | See Remarks | Jan 7, 2026 | Sell | $5.88 | 5,014 | $29,477.31 | 155,907 | |
| AUERBACH ALAN H | PBYI | President and CEO | Jan 7, 2026 | Sell | $5.88 | 18,012 | $105,892.55 | 7,145,951 | |
| NOUGUES MAXIMO F | PBYI | Chief Financial Officer | Jan 6, 2026 | Sell | $5.84 | 4,540 | $26,531.76 | 193,284 | |
| HUNT DOUGLAS M | PBYI | See Remarks | Jan 6, 2026 | Sell | $5.84 | 3,973 | $23,218.21 | 155,907 | |
| AUERBACH ALAN H | PBYI | President and CEO | Jan 6, 2026 | Sell | $5.84 | 16,938 | $98,985.67 | 7,145,951 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 26, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 26, 2026 · 100% conf.
AI Prediction SELL
1D
-4.19%
$7.28
Act: -25.13%
5D
-10.06%
$6.84
Act: -18.03%
20D
-6.98%
$7.07
Price: $7.60 Prob +5D: 0% AUC: 1.000
0001437749-26-005869
pbyi20260204_8k.htm
false 0001401667
0001401667
2026-02-26 2026-02-26
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 26, 2026
PUMA BIOTECHNOLOGY, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware
001-35703
77-0683487
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
10880 Wilshire Boulevard, Suite 1700
Los Angeles, California 90024
(Address of principal executive offices) (Zip Code)
(424) 248-6500
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
symbol
Name of each exchange
on which registered
Common Stock, par value $0.0001 per share
PBYI
The Nasdaq Stock Market LLC
(Nasdaq Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02
Results of Operations and Financial Condition.
On February 26, 2026, Puma Biotechnology, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.
The information in this Item 2.02, including the accompanying exhibit, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Item 2.02 shall not be incorporated by reference into any filing pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
99.1
Press Release dated February 26, 2026.
104
Cover Page Interactive Data File (formatted as inline XBRL).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PUMA BIOTECHNOLOGY, INC.
Date: February 26, 2026
By:
/s/ Alan H. Auerbach
Alan H. Auerbach
Chief Executive Officer and President
2025 Q3 Q3 2025 Earnings
8-K Nov 6, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 6, 2025
0001437749-25-033604
pbyi20250901_8k.htm
false 0001401667
0001401667
2025-11-06 2025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 6, 2025
PUMA BIOTECHNOLOGY, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware
001-35703
77-0683487
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
10880 Wilshire Boulevard, Suite 2150
Los Angeles, California 90024
(Address of principal executive offices) (Zip Code)
(424) 248-6500
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
symbol
Name of each exchange
on which registered
Common Stock, par value $0.0001 per share
PBYI
The Nasdaq Stock Market LLC
(Nasdaq Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02
Results of Operations and Financial Condition.
On November 6, 2025, Puma Biotechnology, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.
The information in this Item 2.02, including the accompanying exhibit, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Item 2.02 shall not be incorporated by reference into any filing pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
99.1
Press Release dated November 6, 2025.
104
Cover Page Interactive Data File (formatted as inline XBRL).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PUMA BIOTECHNOLOGY, INC.
Date: November 6, 2025
By:
/s/ Alan H. Auerbach
Alan H. Auerbach
Chief Executive Officer and President
2025 Q2 Q2 2025 Earnings
8-K Aug 7, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 7, 2025
0001437749-25-025463
pbyi20250724_8k.htm
false 0001401667
0001401667
2025-08-07 2025-08-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 7, 2025
PUMA BIOTECHNOLOGY, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware
001-35703
77-0683487
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
10880 Wilshire Boulevard, Suite 2150
Los Angeles, California 90024
(Address of principal executive offices) (Zip Code)
(424) 248-6500
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
symbol
Name of each exchange
on which registered
Common Stock, par value $0.0001 per share
PBYI
The Nasdaq Stock Market LLC
(Nasdaq Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02
Results of Operations and Financial Condition.
On August 7, 2025, Puma Biotechnology, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.
The information in this Item 2.02, including the accompanying exhibit, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Item 2.02 shall not be incorporated by reference into any filing pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
99.1
Press Release dated August 7, 2025.
104
Cover Page Interactive Data File (formatted as inline XBRL).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PUMA BIOTECHNOLOGY, INC.
Date: August 7, 2025
By:
/s/ Alan H. Auerbach
Alan H. Auerbach
Chief Executive Officer and President
Latest Puma Biotechnology Inc News
PBYI Breaking Stock News: Dive into PBYI Ticker-Specific Updates for Smart Investing
Compare PBYI vs Leading Stocks
See how PBYI stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PBYI Puma Biotechnology Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.